An intensive week-long introduction to translational cancer research – including cancer medicine, the clinical cancer research environment, and collaborative team science – for basic scientists who are predoctoral students and postdoctoral fellows, early-career scientists, and senior scientists in transition to translational research.

This workshop is hosted in close collaboration with the Dana-Farber Cancer Institute/Harvard Cancer Center, comprised of Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Children’s Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital.

The Translational Cancer Research for Basic Scientists Workshop will provide basic research scientists with a better understanding of translational research, teach them how to adapt their research for maximum clinical impact, and help them transition into a new career in translational cancer medicine. This innovative workshop addresses many aspects of translational research including leading multidisciplinary teams, working collaboratively and effectively with industry partners, recognizing the unique needs and environment of the clinic and clinical laboratories, dealing with the regulatory and compliance issues in translational science, and understanding the perspective of the patient in order to place research questions into a broader context. During the course of the week, attendees will gain perspective and background knowledge of the disease from translational scientists in academia and industry, clinicians, and patients, while learning about the latest methods and approaches in cutting-edge translational cancer research.

Previous workshops consisted of over 25 faculty members providing core didactic lectures, nearly 15 additional healthcare professionals participating as lab/discussion leaders, and more than 35 clinicians supervising offsite visits. We are excited to offer this outstanding educational program again, to promote the professional development of early-career investigators in translational cancer research.